🧠Did you know? March is Brain Injury Awareness Month. Read my latest column on navigating hypoparathyroidism's unknown purpose and clear path forward.
Yorvipath represents a breakthrough in hypoparathyroidism treatment. This article explores this new therapeutic option and its potential benefits.
Yorvipath (TransCon PTH) is a sustained-release PTH analog designed to provide more consistent hormone levels throughout the day. Unlike traditional calcium and vitamin D supplements, Yorvipath directly replaces the missing PTH hormone.
Yorvipath uses a transcon technology that:
Studies have shown that Yorvipath can:
Discuss with your healthcare provider whether Yorvipath is appropriate for your situation. Consider:
If you're interested in Yorvipath: